1870-249X 1870-249X S1870-249X2018000200259 10.29356/jmcs.v62i2.390 Mexico Mexico 00 06 2018 00 06 2018 62 2 259 269

2011 80 1258-70 2007 72 247-59 2004 43 825-35 2002 39 1-266 2014 9 2011 305 1553-9 2004 34 50-7 2012 8 301-6 Alberta Kidney Disease Network 2011 6 1418-26 2011 32 89-95 Diabiopsies Study, G 2004 19 1437-40 2003 52 1031-5 2007 106 36-42 2009 111 9-15 2006 69 2131-47 2005 16 1733-41 1997 99 342-8 2009 5 463-8 2005 54 1626-34 2008 19 2035-7 2016 27 354-70 2013 59 69-75 1995 46 223-34 2017 17 63 1989 264 21597-602 2014 2 49-53 1998 54 193-202 2014 21 318-26 2012 5 155-64 2003 61 93-101 2006 17 1886-95 2008 26 1849-59 2012 49 15-24 1996 156 286-9 2000 15 1379-83 ALTITUDE Investigators 2012 367 2204-13 2016 7 10330 2006 29 595-600 Diabetics Exposed to Telmisartan and Enalapril Study Group 2004 351 1952-61 1995 69 397-403 1998 18 35-41 1991 266 11649-53 2004 61 313-29 2002 25 1807-20 1984 98 1591-6 2003 285 40-8 1997 40 15-22 2015 3 51-6 UKPDS GROUP 2003 63 225-32 2006 17 339-52 RENAAL Study Investigators 2001 345 861-9 Collaborative Study Group 2001 345 851-60 MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators 2002 106 672-8 Angiotensin II Receptor Antagonist Telmisartan Micardis in Isolated Systolic Hypertension (ARAMIS) Study Group 2005 23 2055-61 2005 16 30-3 2005 28 498 2004 43 993-1002 2005 64 476-8 2004 27 457-64 2007 32 261-8 2007 39 372-6 2010 33 304-12 2003 83 253-307 2014 5 763-76 2010 55 824-34 2004 144 92-9 2013 85 54-8 2012 32 377-84 2015 10 10-33 2012 34 17-23